Open AccessmiR‐429 expression in bladder cancer and its correlation with tumor behavior and clinical outcome
Author(s) -
Wu ChiaLun,
Ho JarYi,
Hung ShunHsing,
Yu DahShyong
Publication year - 2018
Publication title -
the kaohsiung journal of medical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.439
H-Index - 36
eISSN - 2410-8650
pISSN - 1607-551X
DOI - 10.1016/j.kjms.2018.01.001
Subject(s) - medicine , bladder cancer , stage (stratigraphy) , hazard ratio , proportional hazards model , oncology , urology , univariate analysis , clinical significance , transitional cell carcinoma , cancer , multivariate analysis , gastroenterology , paleontology , confidence interval , biology
We previously showed that microRNA‐429 (miR‐429) played an important role in epithelial–mesenchymal transition (EMT) of urothelial cell carcinoma of the bladder. We herein evaluated the expression of miR‐429 in bladder cancer and its potential relevance to clinicopathological characteristics and patient survival. Relative expression levels of miR‐429 in surgical bladder cancer tissue specimens obtained from 76 patients with bladder cancer were measured by chromogenic in situ hybridization. miR‐429 expression was significantly higher in specimens from alive patients than expired patients in both of 5‐year overall survival (OS) (0.59 ± 0.09 vs. 0.27 ± 0.12; p < 0.05) and 5‐year recurrence‐free survival (RFS) (0.63 ± 0.10 vs. 0.33 ± 0.10; p < 0.05). The univariate Cox proportional hazards analysis revealed that tumor grade, stage, and miR‐429 expression were significantly associated with patient survival. In multivariate analysis, tumor stage and miR‐429 expression were significantly associated with 5‐year OS (hazard ratio [HR] 4.70, p < 0.001) and 5‐year‐RFS (HR 2.20, p < 0.05). The Kaplan–Meier analysis showed that patients with miR‐429 expression had significantly better 5‐year OS and 5‐year RFS rates than those without miR‐429 expression (84.4% vs. 61.4%, p < 0.05 and 71.9% vs. 45.5%, p < 0.05, respectively). miR‐429 may be considered as an adjunctive prognostic marker in addition to tumor grade and stage in bladder cancer.